A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.
Authors
Hamid, OIlaria, R
Garbe, C
Wolter, P
Maio, M
Hutson, T
Arance, A
Lorigan, Paul C
Lee, J
Hauschild, A
Mohr, P
Hahka-Kemppinen, M
Kaiser, C
Turner, P
Conti, I
Grob, J
Affiliation
The Angeles Clinic and Research Institute, Los Angeles, California.Issue Date
2014-07-01
Metadata
Show full item recordAbstract
Tasisulam sodium (hereafter referred to as tasisulam) is a novel, highly albumin-bound agent that demonstrated activity in a phase 2 melanoma study.Citation
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. 2014, 120 (13):2016-24 CancerJournal
CancerDOI
10.1002/cncr.28635PubMed ID
24676877Type
ArticleLanguage
enISSN
1097-0142ae974a485f413a2113503eed53cd6c53
10.1002/cncr.28635